Skip to main content
NewslettersWatchlist

Amylyx Pharmaceuticals Inc(AMLX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.8200
Day High1.9000
Open:1.8300
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
TheNewswire.com
AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
AMLX IMPORTANT DEADLINE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
AMLX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
AMLX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
Kaplan Fox & Kilsheimer LLP Reminds Amylyx (NASDAQ: AMLX) Investors of a Class Action Lawsuit and April 9, 2024 Lead Plaintiff Deadline
The Globe and Mail
Market movers: Stocks seeing action on Thursday - and why
TheNewswire.com
AMLX FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
AMLX DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
AMLX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, A LONGSTANDING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
Barchart
Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat
TheNewswire.com
Amylyx Pharmaceuticals (NASDAQ: AMLX) - Kaplan Fox & Kilsheimer LLP Reminds Amylyx Investors of a Class Action Lawsuit and Upcoming Deadline and Encourages Investors with Significant Losses to Contact the Firm
Barchart
Stocks Slide After U.S. Unemployment Report
Barchart
Stocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cuts
TheNewswire.com
NATIONALLY RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX
TheNewswire.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

Profile

Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.